Toth Financial Advisory Corp Buys Stake in Incyte Corporation

The investment firm adds 12,280 shares of the biopharmaceutical company to its portfolio.

Apr. 4, 2026 at 11:54am

Got story updates? Submit your updates here. ›

Toth Financial Advisory Corp has acquired a new position in Incyte Corporation (NASDAQ:INCY), purchasing 12,280 shares of the biopharmaceutical company's stock during the fourth quarter. The shares are valued at approximately $1.2 million.

Why it matters

The investment by Toth Financial Advisory Corp in Incyte reflects ongoing institutional interest in the biopharmaceutical company, which develops and commercializes novel therapies for cancer, autoimmune disorders, and rare diseases. Incyte's flagship product is the JAK inhibitor Jakafi, approved for the treatment of myelofibrosis and polycythemia vera.

The details

According to a recent 13F filing, Toth Financial Advisory Corp purchased the 12,280 shares of Incyte in the fourth quarter. The investment firm joins other major institutional investors that have also taken positions in Incyte, including AustralianSuper Pty Ltd, Rakuten Investment Management Inc., and Massachusetts Financial Services Co. MA.

  • Toth Financial Advisory Corp acquired the Incyte shares during the fourth quarter of 2025.

The players

Toth Financial Advisory Corp

An investment management firm that has taken a new position in Incyte Corporation.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

Toth Financial Advisory Corp's investment in Incyte Corporation reflects the ongoing institutional interest in the biopharmaceutical company and its pipeline of innovative therapies, particularly its flagship product Jakafi.